Compare HBIO & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | LSTA |
|---|---|---|
| Founded | 1901 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 29.2M |
| IPO Year | 2000 | 2000 |
| Metric | HBIO | LSTA |
|---|---|---|
| Price | $6.69 | $3.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $15.00 |
| AVG Volume (30 Days) | 72.3K | ★ 91.5K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,176,000.00 | $35,283,868.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.28 | $1.81 |
| 52 Week High | $7.00 | $5.07 |
| Indicator | HBIO | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 70.00 | 27.42 |
| Support Level | $0.47 | $1.91 |
| Resistance Level | N/A | $4.95 |
| Average True Range (ATR) | 0.52 | 0.30 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 90.85 | 19.83 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.